To validate the generated MmuPV1 plasmid (Figure 1E) in vitro, we transfected mouse embryonic fibroblasts (MEFs) (isolated from R26R-lox-STOP-lox-eYFP mice) with the generated MmuPV1-lox-Cre-lox plasmid (MmuPV1-Cre) or with the control plasmid, pBABE-GFP. As expected, we detected the function of the Cre recombinase which facilitates the YFP expression in the MmuPV1-lox-Cre-lox transfected cells by immunofluorescence (IF) (Figure 1A). Additionally, we isolated DNA from these transfected cells and determined the PCR amplification of the Cre sequence and sequence flanking the Cre cassette (Cre loss), showing the recombination of the MmuPV1-lox-Cre-lox plasmid after Cre expression (Figure 1B).

Figure 1

Download asset Open asset

Lastly, we detected the presence of MmuPV1 viral transcripts E1/E4, L1 and E6 via RT-PCR analysis in MmuPV1-lox-Cre-lox transfected cells but not in pBABE-GFP transfected cells (Figure 1C–D). Together, these results validate that the constructed MmuPV1-lox-Cre-lox plasmid can indeed lead to reporter activation, Cre-excision, and MmuPV1 genome recircularization in vitro.

Next, we used the plasmid in mice. It is known that infection with MmuPV1 is mainly cleared by the functions of the CD8+T cell-dependent adaptive immunity (Handisurya et al., 2014). Therefore, immunocompromised mice are more susceptible to the mouse papillomavirus. Thus, we transiently immunocompromised mice before delivering the MmuPV1-lox-Cre-lox plasmid by using UV-B radiation. UV-B was shown to suppress the adaptive immune response, whereas the innate immune response remains largely unaffected (Uberoi et al., 2016).

Following the UV-B radiation, the base of the tail skin of R26R-lox-STOP-lox-eYFP mice was superficially abraded with a pipette tip to expose the tail basal layer. Then, MmuPV1-lox-Cre-lox plasmid was delivered and skin samples were harvested at the specified time points to check the presence of YFP expression by IF (Figure 2A).

Figure 2

Download asset Open asset

We observed characteristic clones of YFP-expressing cell population in the skin indicative of heritable YFP activation in a skin basal cell. Clones were most prominent at day 3 and day 5 after plasmid delivery (Figure 2B, indicated with white lines). Additionally, we were able to follow-up YFP+ cells at later time points. These results indicate that our model can indeed be used as an in vivo lineage-tracing model for MmuPV1, where virus-hosting cells and their progeny can be individually observed via their genetically induced YFP expression.

As a control for our lineage-tracing model, we use CAG-Cre plasmid which drives the expression of a self-deleting Cre recombinase, just as in the MmuPV1-lox-Cre-lox plasmid, but it does not encode any MmuPV1 genes. As performed above, pCAG-Cre was delivered to R26R-lox-STOP-lox-eYFP mice after UV-B irradiation and tail skin scarification. Tail skins were isolated and treated in an identical manner as MmuPV1-treated tissues (Figure 2C, indicated with white lines).

We also examined the presence of the viral genes and transcripts in the cells of the same tissue samples and same time points as above. Firstly, we used the RNA in situ hybridization assay of RNAscope to check for the expression of MmuPV1 transcripts, E1/E4 and E6/E7. We observed that in the cells that have taken up the MmuPV1-lox-Cre-lox plasmid, E6/E7 transcripts started to appear as early as 3 days post-delivery (p.d.) and peaked around day 7 p.d. (Figure 3A), whereas the E1/E4 transcripts were detected at day 5 p.d. onward and peaked at day 10 p.d. (Figure 3B). Furthermore, we did not detect any of the tested MmuPV1 viral transcripts in the cells that have taken up the CAG-Cre plasmid since the viral genome of MmuPV1 is lacking in this control plasmid (Figure 3C–D). Additionally, we distinguished the viral RNA signal from the viral genomic DNA signal by treating the tissue sections with DNAse and/or RNAse prior to probe hybridization in which we confirmed that the majority of the observed signal for MmuPV1-E6/7 and E1/E4 was indeed viral RNA signal (Figure 3—figure supplement 1A, B).

Figure 3 with 1 supplement see all

Download asset Open asset

To confirm the presence of genome on the skin surface, we swabbed the surface of the treated tail skins and washed the swabs to remove cells prior to collecting the skin tissue for the above-mentioned assays. To verify the anticipated recircularization of the MmuPV1 plasmid occurred in vivo as well, we isolated DNA to determine the PCR amplification of the sequence flanking the Cre cassette (Cre loss) (Figure 3E, Figure 3—figure supplement 1C). We also assessed the presence of the L1 gene of MmuPV1 via PCR as a way of confirming the presence of the viral genome on the skin surface; GAPDH was used as a housekeeping gene (Figure 3E, Figure 3—figure supplement 1C).

As expected, at day 0, we did not observe any viral transcripts, genes, or the Cre loss sequence. However, we detected the Cre loss and the MmuPV1-L1 sequences at day 5 and day 10 samples of the skin surface (Figure 3E), whereas CAG-Cre control samples showed no signal as expected (Figure 3—figure supplement 1C). The presence of the recircularized MmuPV1 plasmid on the surface of the skin could be a result of the eventual migration of the progeny cells to the superficial layer from the initially MmuPV1-harboring cell at the basal layer and shedding the viral particles on the skin surface. However, since the level of the detected signal is considerably low, as can be seen in Figure 3E or Figure 3—figure supplement 1C, we believe that the amount of correctly recombined MmuPV1-lox-Cre-lox plasmid after Cre expression is rather low but still present in vivo. At day 30 time point, we did not detect any viral genome on swabs of the tail skin even though we still detect YFP+ cells at this time point, albeit at low levels (Figure 4A). This might be indicative of the greatly reduced presence (below limit of detection) or clearance of the virus on the skin.

Figure 4 with 2 supplements see all

Download asset Open asset

Figure 4—source data 1

The source data of FACS for Figure 4 and its supplements is included in a Microsoft Excel spreadsheet called “Source data - FACS”.

https://cdn.elifesciences.org/articles/72638/elife-72638-fig4-data1-v1.xlsx

Download elife-72638-fig4-data1-v1.xlsx

Furthermore, we checked whether the formation of virions is occurring in our system following the initial plasmid delivery and the consequent recombination and genome recircularization. Using transmission electron microscopy (TEM), we were able to visualize virion-like structures in the perinuclear area of epithelial cells in all the MmuPV1-Cre treated mice, whereas none of these structures were observed in mice treated with the control CAG-Cre plasmid (Figure 3F). Together, we were able to detect the MmuPV1 transcripts of E1/E4 and E6/E7 in the cells which harbor the MmuPV1-lox-Cre-lox plasmid and also confirmed the recombination of the MmuPV1-lox-Cre-lox plasmid after Cre expression by detecting the sequence flanking the Cre cassette (Cre loss).

To provide proof of principle that our model system may be used to answer question regarding papillomavirus biology and taking advantage of the ability to detect YFP expressing cells, we applied the plasmids to the tail skin of R26R-lox-STOP-lox-eYFP mice as mentioned above. Then, skin samples were harvested at the specified time points and processed and stained for flow cytometric analysis.

Firstly, we applied a standard gating strategy to exclude dead and doublet cell populations (Figure 4—figure supplement 1A). Then, we detected the YFP expressing cells and compared numbers and frequencies between groups and different time points (Figure 4A, Figure 4—figure supplement 1B). We found that both numbers and percentages of YFP+ cells were much higher in MmuPV1 samples at day 5 p.d., which decreased overtime as seen at day 10 and day 30 p.d. Whereas, pCAG-Cre samples only start to have increased YFP+ cells around day 10 p.d. (Figure 4A, Figure 4—figure supplement 1B). These results are also in line with the IF data we saw previously and can indicate to a difference in the actual amount of plasmid delivered to the tissue or the different dynamics of the plasmids due to the presence of the MmuPV1 genes. Furthermore, coinciding with the increased number of YFP+ cells, we observed that MmuPV1-harboring cells exhibit significantly increased levels of Ki-67 around day 5 p.d. compare to other time points (Figure 4B, Figure 4—figure supplement 1C). We further directly visualized Ki-67-positive cells by immunohistochemistry (IHC) in the regions of infected skin where we previously detected the MmuPV1 transcripts via RNAscope and observed that the cells harboring MmuPV1-Cre plasmid indeed exhibit higher proliferation around day 5 p.d. compare to the cells harboring CAG-Cre control plasmid (Figure 4D).

Papillomaviruses have previously been reported to reduce MHC-I expression, but evidence was generated in vitro (Georgopoulos et al., 2000; Heller et al., 2011; Li et al., 2010). To evaluate the levels of MHC-I specifically on the cell surface of the MmuPV1-harboring cells, we used flow-cytometry to interrogate MHC-I levels within the YFP+ population. Interestingly, we observed significantly lower expression of MHC-I molecules on the YFP+ cells of MmuPV1-treated tissues at day 5 p.d., whereas YFP+ cells in control treated tissues exhibit increased MHC-I expression at this time point, presumable due to YFP neo-antigen expression (Figure 4C, Figure 4—figure supplement 1D). These effects waned at later time points. Our results agree with previous in vitro studies and indicate a possible immune evasion strategy by the MmuPV1 where the virus is causing a decreased expression of MHC-I molecules on the cell surface to reduce the antigen exposure to the immune cells.

It is important to note, that the differences in proliferation and MHC- I expression were specific to the YFP + cells within the tissue. Also, within the same tissues, we analyzed the Ki-67 and MHC-I levels of the neighboring YFP- cells which have not taken up the given plasmid (Figure 4—figure supplement 2). We observed no significant difference between time points or between the YFP- cell population of the MmuPV1 plasmid-treated tissue and the CAG-Cre plasmid-treated tissue (Figure 4—figure supplement 2A, B). These results suggest that any differences observed are specific to plasmid uptake.

Together, these results indicate that during early acute infection, MmuPV1 causes increased proliferation which may be accompanied by decreased antigen presentation. Additionally, here we show that our novel in vivo lineage-tracing model can be used as a tool to answer such key questions in the field of MmuPV1 biology.

Here, we describe a novel in vivo lineage-tracing model for MmuPV1 infected cells in laboratory mice (Mus musculus). We propose that the ability to trace MmuPV-1 harboring cells and their progeny by microscopy, as well as to quantify and analyze by means of flow-cytometry renders this model a suitable and convenient tool for answering a variety of outstanding questions in papillomavirus biology (Lambert et al., 2020). Particularly, we believe that the novel model described here can be used to investigate the early effects of papillomavirus on the target cells, transcriptional and phenotypic changes of the papillomavirus-harboring cells during the acute phase of the infection, and investigate the initial viral-host immune interactions.

To generate a plasmid with a self-deleting Cre sequence and the full MmuPV1 genome, we combined sequences from four plasmids: puC19-MmuPV1 (gift from Paul F. Lambert), pCAG-cre (a gift from Connie Cepko (Addgene plasmid # 13775; http://n2t.net/addgene:13775; RRID: Addgene_13775)), small_pMA-T, and large_pMA-T (synthesized by Invitrogen). To construct the final plasmid, we first PCR amplified the sequence in large_pMA-T that contains the lox and part of the E6 sequence using primers to introduce PstI and HindIII restriction sites in the 5’ and 3’ ends of the sequence, respectively. Using PstI and HindIII, we cloned lox-E6 in the pCAG-Cre plasmid. In this new plasmid, we subcloned the L1-lox sequence from small_ pMA-T plasmid using blunt end ligation (L1-Lox sequence was isolated using SacI and KpnI restriction enzymes, the Cag-cre plasmid was digested with SalI and T4 DNA polymerase was used to generate blunt ends). We refer to this plasmid as plox-cre-lox which was sequenced to confirm the correct insertion of L1-lox-Cre-lox-E6 sequence. To generate the plasmid for animal infection, we removed the ampicillin bacterial selection cassette from lox-cre-lox and MmuPV1 plasmids using XhoI and XbaI. The two fragments (lox-cre-lox and MmuPV1) were gel purified and ligated overnight at 16 °C (ligation was done using a ratio of 1:2.5, MmuPV1 to lox-cre-lox). Complete plasmid sequences are provided in the supplementary file. pBABE GFP (a gift from William Hahn [Addgene plasmid # 10668; http://n2t.net/addgene:10668; RRID:Addgene 10668]) plasmid was used as a control for the in vitro experiments.

MEFs were used for in vitro transfections. MEFs were isolated from C57BL/6 R26R-lox-STOP-lox-eYFP pregnant mice at 13.5 days post-conception. The embryos were harvested from the mouse uterus and placed washed in PBS (GibcoTM) and penicillin-streptomycin (P/S) (Gibco) antibiotics. The embryos were transferred in a 10 cm dish containing PBS and P/S, and all the membranes were removed to allow embryo isolation. The embryo’s head was cut below the eye and visible viscera such as the liver were removed. The embryo was then transferred to a fresh 10 cm dish containing 0.05% trypsin-EDTA ×1 (Gibco) in PBS and was chopped with a razor blade. The dish was incubated in a 37 °C incubator for 20 min, and the cells were pipetted up and down until a single-cell suspension was obtained which was also incubated for another 20 min. Media was added in the dish, mixed well, and the cells were then transferred to T75 bottles until confluent. MEFs were maintained in Dulbecco’s Modified Eagle Medium (DMEM, Gibco, cat. no 41965039) supplemented with 10% v/v fetal bovine serum (FBS, Gibco, cat. no 10500064) and 1% v/v penicillin/streptomycin (Gibco, cat. no 15070063). In vitro transfections were performed with FuGENE6 Transfection Reagent (Promega, cat. no E2691) as described previously (Hong et al., 2009).

DNA and RNA isolations were performed using TRIZOL (Invitrogen) following the manufacturer’s instructions. We used RT-PCR to confirm expression of Cre (Cre forward primer: 5’-ACG AGT GAT GAG GTT CGC AA-3’, Cre reverse primer: 5’-CGC CGC ATA ACC AGT GAA AC-3’, GAPDH was used as a housekeeping gene) and PCR to determine lox-recombination and removal of the sequence flanked by loxp sites from the plasmid (Cre loss forward primer: 5’-ACT GTT TAC TGG GGG CTT AC -3’ and cre loss reverse primer: 5’-GGC AGA ACA CAA TGG AAC TC-3’). RT-PCR analysis was performed to assess the presence of viral transcripts from pBABE GFP and MmuPV1-lox-Cre-lox transfected MEFs. The following primer pairs were used and data were analyzed with Rotorgene 6000 Series Software (Qiagen): GAPDH: 5’-ACT CCA CTC ACG GCA AAT TC-3’ and 5’-TCT CCA TGG TGG TGA AGA CA-3’, E1/E4: 5’-GAA CTC TTC CCA CCG ACA CC-3’ and 5’-AAG GTC CTG CAG ATC CCT CA-3’, E6: 5’-ATG GAA ATC GGC AAA GGC TA-3’ and 5’-CTT TTC AGA GGC AGT AAG GA-3’, L1: 5’-TAT ATA ACA TCA TCG GCA AC-3’ and 5’- TGC TTC CCC TCT TCC GTT TT-3’.

R26R-lox-STOP-lox-eYFP (Jackson lab stock number #006148, https://www.jax.org/strain/006148) immunocompetent mice, obtained from the mouse facility of the Cyprus Institute of Neurology and Genetics (CING), were of a pure C57BL/6 genetic background. All mice were used at 6–12 weeks of age and were sex- and age-matched within experiments. All the genotypes were confirmed by means of PCR. Mice were housed at the University of Cyprus, in accordance with regulations and protocols approved by the Cyprus Ministry of Agriculture.

The back skin of 6–9 weeks old female R26R-lox-STOP-lox-eYFP mice were shaved and a single dose of 1000 mJ/cm² UV-B irradiation was applied for immunosuppression as previously described (Dorfer et al., 2021). Following the UV-B radiation, the mice were given at the same day with 2 × 10⁹ DNA copies of MmuPV1-lox-Cre-lox or CAG-Cre plasmid in a 10 µl of PBS solution applied at the base of the tail skin by a superficial scarification with a pipette tip to expose the tail basal layer. Tissue samples were then harvested at the specified time points. Tail skin was selected for plasmid delivery for practical reasons (ability to track area where plasmid was delivered and fewer hairs which place barriers on cell dissociation for FACS experiments).

Tail tissue sections from the base of the tail were harvested in a rectangular manner and were cut in half, washed with ×1 PBS, fixed in 4% paraformaldehyde (PFA), and embedded in optimal cutting temperature compound and frozen on dry ice before storing in –80°C. Frozen tissues were then sectioned (17 microns thick) using a cryostat and mounted on the positively charged Thermo Scientific SuperFrost Plus Adhesive slides.

MmuPV1 viral transcripts were detected using RNAscope 2.5 HD Assay-Brown (cat. no. 322300) (Advanced Cell Diagnostics, Newark, CA) according to manufacturer instructions with probes specific for MmuPV1 E6/E7 (Cat #409771) and for MmuPV1 E1/E4 (Cat #473281) as described previously (Spurgeon and Lambert, 2019; Xue et al., 2017). Tissue sections were treated following protease treatment for 30 min at 40°C followed by the probe hybridization. Tissues were then counterstained with hematoxylin and mounted in Cytoseal media (Thermo Fisher Scientific). To distinguish viral RNA signal from viral genomic DNA signal, tissue sections were treated following protease treatment and prior to probe hybridization with 20 units of DNAse I (Thermo Fisher Scientific, #EN0521), or DNAse I combined with 500 µg RNAse A (Qiagen, #1006657) plus 2000 units RNAse T1 (Fermentas, Waltham, MA, #EN0542) for 30 min at 40 °C.

For IF, after antigen retrieval was performed in a microwave using 10 mM citrate buffer, the tissue sections were permeabilized and blocked at room temperature for 1 hr with a blocking buffer containing 0.5% skim milk powder, 0.25% fish skin gelatin, and 0.5% Triton X-100. Then, sections were washed with PBS and stained with purified primary antibodies in blocking buffer at 4°C overnight. Tissues were then washed with ×3 PBS, stained with secondary antibodies at room temperature for 1 hr, counterstained with Hoechst dye, mounted in Prolong mounting media (Prolong Gold Antifade reagent, Invitrogen, cat. no. P36930), and sealed with nail polish. Similar approach was used for the in vitro experiments where cultured cells were stained with anti-GFP/YFP antibody to enhance the YFP signal and Hoechst dye to label DNA as mentioned above.

For immunohistochemical (IHC) staining, tissue sections were fixed again in 4% PFA at 4°C for 15 min followed by an antigen retrieval step in a microwave using 10 mM citrate buffer. Quenching of endogenous peroxidase activity was accomplished by incubation with 1% hydrogen peroxidase. Sections were blocked with 5% Normal Horse Serum and stained with Ki-67 recombinant rabbit monoclonal antibody (Thermo Fisher Scientific, MA5-14520, 1:100) in blocking buffer at 4°C overnight. Then, sections were washed in PBS and incubated with horse radish peroxidase (HRP)-conjugated goat-α-rabbit secondary antibody (Thermo Fisher Scientific, 31460, 1:250). Reaction product was visualized with a diaminobenzidine (DAB) peroxidase substrate kit (SK-4100; Vector Laboratories, Burlingame, CA).

The following antibodies were used for detecting mouse antigens by immunofluorescent staining: rabbit-anti-K14 (polyclonal, 1:1000, Covance, PRB-155b), goat-anti-GFP (polyclonal, 1:100, SICGEN, AB0020-200), Alexa Fluor 488 donkey-anti-goat (polyclonal, 1:250, Jackson, 705-545-147), Alexa Fluor 488 donkey-anti-mouse (polyclonal, 1:250, Jackson, 715-545-150), FITC donkey-anti-rabbit (polyclonal, 1:250, Jackson, 711-095-152), and Alexa Fluor 594 donkey-anti-rabbit (polyclonal, 1:250, Jackson, 711-585-152).

After mice were sacrificed and tail skins were extracted as described above, the tail samples were incubated in a 0.25% trypsin containing EDTA solution (Sigma-Aldrich) overnight at 4°C. The next day, epidermis was separated from dermis by using tweezers, the tissue was cut into small pieces and was mechanically dissociated by using a handheld homogenizer (POLYTRON PT 1200 E). Subsequently, the resulting single cell suspensions were washed with PBS and cells were incubated with fluorescently conjugated antibodies for 30 min at 4°C. After marker staining, cells were fixed and permeabilized for 10 min with 2 × BD lysing solution (BD Biosciences) + 0.1% Tween, washed, and then stained in PBS for intracellular Ki-67 staining. The following antibodies (indicating target-fluorochrome) were purchased from Biolegend and were used according to the manufacturer’s instructions: MHC-I(H-2Kb)-Brilliant violet 421, Ki-67-PerCP/Cy5.5 and TLR9-PE. Multiparametric flow cytometric analysis was performed using a Bio-Rad S3e Cell Sorter flow cytometer and analyzed using FlowJo software (Treestar). The population of live cells was detected depending on their size and complexity (FSC-SSC gate) and later the doublets were excluded (FSC-Height/FSC-Area gate).

For the visualization of tissue sections for RNAscope analysis, the Zeiss Axio Observer.A1 microscope was used. The images were prepared with Photoshop CS6 software.

Samples were fixed in 2.5% glutaraldehyde in phosphate buffer (0.1 M, pH = 7.2) for a minimum of 24 hr at 4°C. Then, the samples were washed in phosphate buffer (0.1 M, pH = 7.2), post-fixed in 1% osmium tetroxide, dehydrated in graded ethanol, cleared in propylene oxide, and embedded in an epon/araldite resin mixture and polymerized at 60°C for 24 hr. Semithin sections of 1 μm thickness were cut by using an ultra-microtome (Leica Reichert UCT, Vienna, Austria), stained with toluidine blue, and examined in a light microscope. Silver/gold interference color ultrathin sections were cut and mounted on 300 mesh copper grids, contrasted with uranyl acetate and lead citrate, before being examined under a TEM (TALOS L120C, FEI, USA) operating at 120 kV. Images were collected using the Ceta camera installed on the TEM. Uranyl acetate, Lead Citrate, Toluidine Blue, Araldite Resin, Agar 100 Resin, Dodecenyl Succinic Anhydride (DDSA), Tri-Dimethylaminomethyl Phenol (DMP-30), Osmium tetroxide, Glutaraldehyde, and Copper 300 mesh grids were all purchased from AGAR (Essex, UK).

Nonparametric 2-way ANOVA test was performed and statistical significance was considered at p<0.05. Statistical analyses of the data were performed using the GraphPad Prism v.8.0 (La Jolla, CA). All the experiments were performed using at least three biological replicates.

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

We thank the members of the Strati (KS) and Kirmizis (AKY) groups for helpful discussions and sharing of materials, reagents and equipments. We also thank Paul F Lambert for the puC19-MmuPV1 plasmid. This work was funded by grants to KS by the Cyprus Research and Innovation Foundation (INFRASTRUCTURES/1216/0034, OPPORTUNITY/0916/ERC-StG/003, POST-DOC/0916/0111).

This study was carried out in strict accordance with the recommendations in the Guidelines for the Protection of Laboratory Animals of the Republic of Cyprus. The animal facility is licensed by the Veterinary Services (Republic of Cyprus Ministry of Agriculture and Natural Resources), the government body in charge of approving and overseeing laboratory animal work in Cyprus (license number CY.EXP.105) and the protocol was approved by the same authority (License number CY/EXP/PR. L1/2019).

© 2022, Yilmaz et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.